LuCAB临床试验方案:卡巴他赛联合[177Lu]Lu-PSMA-617治疗转移性去势抵抗性前列腺癌的I-II期试验
LuCAB是一项研究者发起的I-II期试验,旨在评估卡巴他赛联合[177Lu]Lu-PSMA-617治疗转移性去势抵抗性前列腺癌的安全性、耐受性和初步疗效。最多38例患者接受最多6剂[177Lu]Lu-PSMA-617(每6周静脉给药,固定剂量7.4 GBq)联合卡巴他赛(每个6周周期的第2天和第23天给药,剂量范围12.5-20 mg/m2,采用传统3+3设计确定最大耐受或给药剂量)。主要目标是评估剂量限制性毒性并确定II期推荐剂量。
要点
- 卡巴他赛联合[177Lu]Lu-PSMA-617拟利用放射增敏与协同作用。
- 入组需PSMA PET/CT阳性(SUVmax ≥ 15)且[18F]F-FDG PET/CT无不一致病灶。
- 采用传统3+3设计确定卡巴他赛的最大耐受或给药剂量。
核心结论
- 研究者假设[177Lu]Lu-PSMA-617与卡巴他赛联合具有协同作用且安全性可接受。
- 主要目标为评估剂量限制性毒性并确定联合方案的II期推荐剂量。
研究设计与样本
- 研究者发起的I-II期试验,计划入组最多38例转移性去势抵抗性前列腺癌患者。
- [177Lu]Lu-PSMA-617每6周静脉给药一次,固定剂量7.4 GBq,最多6剂。
- 卡巴他赛在每个6周周期的第2天和第23天同时给药,剂量范围12.5-20 mg/m2,采用传统3+3设计进行剂量递增。
主要发现
- 截至摘要报告时,研究已开始入组,尚未报告安全性或疗效结果。
- 次要目标包括通过不良事件频率和严重程度进一步评估安全性、评估疗效以及评估治疗开始后前12个月疼痛和健康相关生活质量的变化。
- 将在基线、治疗期间和疾病进展时采集血浆进行循环肿瘤DNA分析,并与临床结局关联以识别潜在疗效或耐药生物标志物。
关键数值与推荐
- 关键入选标准包括经PSMA PET/CT证实PSMA阳性(SUVmax ≥ 15)且[18F]F-FDG PET/CT无不一致病灶的进展性mCRPC。
- 患者须既往接受过多西他赛和雄激素受体通路抑制剂,骨髓和器官功能良好,东部肿瘤协作组体能状态评分为0或1。
- [177Lu]Lu-PSMA-617固定剂量为7.4 GBq,每6周静脉给药一次,最多6剂。
- 卡巴他赛剂量范围为12.5-20 mg/m2,在每个6周周期的第2天和第23天给药。
临床怎么用
- 本方案为研究者发起的I-II期临床试验,旨在确定联合方案的II期推荐剂量,原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
[177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 is a standard treatment for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and an androgen receptor pathway inhibitor. However, for many, responses are short and progression is inevitable. Contributing factors to treatment resistance include molecular heterogeneity with variable PSMA expression, micrometastases that may not absorb sufficient radiation from 177Lu to result in cell death, and inherent or acquired radioresistance because of genomic alterations or the tumor microenvironment. Cabazitaxel is a radiosensitizer and may treat PSMA-negative disease that would otherwise evade targeting by [177Lu]Lu-PSMA-617. We hypothesize that the combination of [177Lu]Lu-PSMA-617 and cabazitaxel will be synergistic with an acceptable safety profile. Methods: This investigator-initiated phase I-II trial aims to evaluate the safety, tolerability, and preliminary efficacy of cabazitaxel and [177Lu]Lu-PSMA-617 in combination. Up to 38 patients with mCRPC will receive up to 6 doses of [177Lu]Lu-PSMA-617 administered intravenously every 6 wk at a fixed dose of 7.4 GBq. Cabazitaxel will be administered concurrently (dose range, 12.5-20 mg/m2) on day 2 and day 23 of each 6-wk cycle, with dose escalation determined using a traditional 3 + 3 design to establish the maximum tolerated or administered dose. Key eligibility criteria include a diagnosis of progressive mCRPC with PSMA-positive disease on PSMA PET/CT (SUVmax ≥ 15) and no sites of discordance on [18F]F-FDG PET/CT. Patients must have received prior docetaxel and an androgen receptor pathway inhibitor, have adequate bone marrow and organ function, and have an Eastern Cooperative Oncology Group performance status of 0 or 1. The primary objective is to assess for dose-limiting toxicities and determine the recommended phase II dose of cabazitaxel and [177Lu]Lu-PSMA-617 in combination. Secondary objectives include further safety evaluation through the measurement of the frequency and severity of adverse events, assessment of efficacy, and evaluation of changes in pain and health-related quality of life over the first 12 mo from treatment commencement. Plasma will be collected at baseline, during treatment, and at disease progression for circulating tumor DNA analysis, which will be correlated with clinical outcomes to identify potential biomarkers of treatment response or resistance. Conclusion: Enrollment commenced in August 2022, with anticipated completion in 2025.
引用
- Kostos L, Buteau JP, Kong G, et al. Clinical Trial Protocol for LuCAB: A Phase I-II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2025. PMID: 39978808. doi:10.2967/jnumed.124.269252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。